U.S. Markets closed

Gilead Sciences, Inc. (GILD.MX)


Mexico - Mexico Delayed Price. Currency in MXN
Add to watchlist
1,287.000.00 (0.00%)
At close: 2:54PM CDT

Gilead Sciences, Inc.

333 Lakeside Drive
Foster City, CA 94404
United States
650-574-3000
http://www.gilead.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees9,000

Key Executives

NameTitlePayExercisedAge
Dr. John C. Martin Ph.D.Exec. Chairman3.76M80.81M65
Dr. John F. Milligan Ph.D.CEO, Pres & Director4.09M48.39M56
Ms. Robin L. WashingtonExec. VP & CFO1.85MN/A54
Mr. Kevin B. Young CBEChief Operating Officer1.82M1.12M59
Dr. Norbert W. Bischofberger Ph.D.Exec. VP of R&D and Chief Scientific Officer2.23MN/A61
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in MXN.

Description

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical needs in Europe, North America, Asia, South America, Africa, Australia, India, and the Middle East. The company’s products include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis C virus and hepatitis B virus; hematology/oncology; cardiovascular; and inflammation/respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., Galapagos NV., and Spring Bank Pharmaceuticals, Inc. The company was founded in 1987 and is headquartered in Foster City, California.

Corporate Governance

Gilead Sciences, Inc.’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.